Form 4: IO Biotech Director Heidi Hunter Granted 35,144 Stock Options

IO Biotech, Inc. Director Heidi Hunter was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

Summary

• Heidi Hunter, a Director of IO Biotech, Inc. (IOBT), was granted 35,144 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these stock options is $1.50 per share.
• The options vest on June 5, 2026, contingent upon Ms. Hunter's continued service to the company.
• In the event of a change of control, 100% of these options will accelerate and vest immediately.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Ms. Hunter beneficially owns 35,144 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholder value and incentivizes long-term commitment. It indicates continued engagement of key personnel.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• The options provide a future incentive for the director to remain with the company and contribute to its success, as vesting is subject to continued service.

Negatives

• The value of the options to the director is contingent on the future stock price of IO Biotech, Inc. exceeding the exercise price of $1.50.
• There is no immediate cash benefit to the director from this grant; the value is realized only upon vesting and subsequent exercise and sale of shares.

Risks

• The stock options are subject to forfeiture if the reporting person's service to the company terminates prior to the vesting date of June 5, 2026.

Future Outlook

The granted stock options are set to vest on June 5, 2026, provided the director continues her service. There is a provision for 100% accelerated vesting upon a change of control, offering a potential future liquidity event for the director under specific circumstances.

Industry Context

The grant of stock options to directors is a common and standard practice within the biotechnology and broader corporate sectors. It serves as a key component of executive and director compensation, designed to attract, retain, and motivate talent by aligning their financial incentives with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The practice of granting stock options to directors is a widely accepted compensation mechanism across various industries, including biotechnology, to foster alignment between leadership and shareholder interests.
• Without specific details on IO Biotech's compensation philosophy, peer group comparisons, or the director's overall compensation package, a detailed assessment against industry benchmarks for the size and terms of this specific grant is not feasible from this document alone.

Related Party Transactions

• Grant of 35,144 stock options to Heidi Hunter, a Director of IO Biotech, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Director (Heidi Hunter): Receives a significant equity incentive, contingent on future company performance and continued service, enhancing her overall compensation.

Next Steps

• The stock options will vest on June 5, 2026, subject to the director's continued service.
• Upon vesting, the director will have the right to exercise the options and purchase common stock at the exercise price of $1.50 per share.

Key Dates

Keywords

IO Biotech, IOBT, Stock Options, Insider Transaction, Form 4, Executive Compensation, Director Compensation, Equity Grant, Beneficial Ownership